Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases.

Eyenovia makes new therapies possible. Our unique delivery platform uses breakthrough piezo-print technology for high-precision micro-dosing. Microdosing allows for fully effective therapies that may also avoid many tolerability and side-effect issues associated with traditional eye drop delivery.

In addition to MicroPineTM, the company is advancing programs for chronic angle closure glaucoma and mydriasis into Phase III clinical programs and preparing registration studies for an OTC product for dry eye. Eyenovia is expected to complete all three of these development programs through registration by 2020. Through these programs, Eyenovia is building a portfolio of superior ophthalmic therapeutics with its proprietary micro-dosing formulations of existing and new molecular entities.

Public ophthalmic companies addressing large markets have achieved attractive market valuations as they developed products through Phase 3 studies and achieved US FDA approval

Eyenovia is developing products for four ophthalmology indications, with three Phase 3 programs planned for 2019. Other companies in ophthalmology have achieved attractive enterprise values while in Phase 3 studies and upon FDA approval. Current examples include Kala Pharmaceuticals, with a single product in Phase 3 for dry eye syndrome, as well as Glaukos and Aerie Pharmaceuticals, each of which has one commercial product addressing glaucoma.


Most conventional front-of-the-eye therapies are administered using 100-year-old legacy eye-dropper pipette technology, consistently overdosing the eye with 30-50 μL of pharmaceutical ingredients and often toxic preservatives and compared to the eye’s natural, physiologic tear film capacity of 7-8 μL. This overdose is associated with many ocular side effects such as hyperemia (eye redness), discomfort, dry eye, foreign body sensation, pigment discoloration, periorbital dermatitis and others. For some topical medications, there are also major cardiovascular side effects such as bradycardia and arrhythmia. High precision micro-dosing delivers doses of 6-8 μL (the volume the eye can hold) in a targeted way, directly coating the corneal surface rather than the conjunctiva, thus reducing collateral tissue exposure and focusing on the cornea where 80% of intraocular drug penetration occurs. In addition, Eyenovia’s smart electronics and mobile e-health technology can track when patients administer doses. This will transform compliance and chronic disease management by empowering patients and physicians for the first time with access to dynamic, real time monitoring and compliance data for a more intelligent and personalized therapeutic paradigm.

Find out more about how Eyenovia is making new therapies possible.
We will send you updates including investor presentations and news on our development programs.
We will not share your contact information with anyone.